What is Bevespi (beclomethasone + glycopyrrolate) and what is it used for?
Bevespi is a prescription inhaler used to treat chronic obstructive pulmonary disease (COPD). It is a combination bronchodilator meant to help open the airways and make breathing easier for people with COPD.
What are the ingredients in Bevespi?
Bevespi contains two active medicines:
- Glycopyrrolate (an antimuscarinic/anticholinergic that helps relax airway muscles)
- Formoterol fumarate (a long-acting beta2-agonist that helps keep airways open)
How is Bevespi taken?
Bevespi is used as an inhaled medicine (delivered via an inhaler device). It’s typically used regularly for maintenance treatment of COPD rather than for quick relief of sudden breathing problems.
Is Bevespi a rescue inhaler for sudden symptoms?
No. Like other long-acting COPD maintenance inhalers, Bevespi is not intended to rapidly treat sudden shortness of breath. Rescue medicines for sudden symptoms are usually separate “fast-acting” inhalers.
What side effects do patients ask about most?
Common questions with COPD inhalers like Bevespi often include side effects such as:
- Dry mouth
- Throat irritation
- Cough
- Trouble urinating or urinary retention (more typical of anticholinergic medicines)
- Tremor or palpitations (more typical of beta2-agonists)
How does Bevespi compare with other COPD inhalers?
Bevespi is an example of a dual bronchodilator approach (LABA + LAMA). Other COPD options can include:
- Different LABA/LAMA combinations
- Triple therapy (LABA + LAMA + inhaled corticosteroid), for some patients with frequent exacerbations
Who should not use Bevespi without clinician guidance?
People with certain heart rhythm problems, significant cardiovascular disease, or urinary retention issues may need extra caution with medicines that include beta2-agonists or anticholinergics. Exact suitability depends on the patient’s medical history and current medications.
Are there patents or market exclusivity issues for Bevespi?
DrugPatentWatch.com tracks patent/exclusivity status for many branded drugs. If you meant a specific “Bevespi class” in the sense of patent class/exclusivity, DrugPatentWatch.com can help identify relevant filings and timelines: https://www.drugpatentwatch.com/
Quick clarification so I answer the right question
“Bevespi class” can mean a few different things (the drug’s therapeutic class, its patent/exclusivity class, or a comparison to similar inhalers). Which meaning are you after—therapeutic class for COPD treatment, or patent/exclusivity classification?
Sources
No sources were provided in the prompt, and I did not use external sources to avoid guessing.